

Toll-free: (888) 92-PHENO P (206) 374-9000 F (206) 374-9009 www.phenopath.com

THIS SECTION FOR PHENOPATH USE ONLY

HEME REQ

PHENOPATH USE ONLY

	EN INFORMAT				Ш	
Facility sp Collection	pecimen collected at n Date	t <u> </u>	lection Time		1	
Multiple specimens submitted: □ Test Separately □ Select Best □ Combine				Select Best		REQUESTING ENTITY NAME & ADDRESS
Specimen	ID	Sublabel	ombine Specimen Source		. 1	Block(s), submitted stained slides and report will be returned to the Ordering
Specimen		Judianei	Specimen source			Physician at the address/FAX listed below (unless otherwise requested):
						-
☐ Blood	☐ Green to	p(s)	Purple top(5)	1	
BM aspi	rate 🔲 Green top ssue in RPMI 🔲 Ly	o(s)	Purple top(S)	Ш	
Body flu	ıid:	•	□ cs	F	Ш	
☐ Paraffin	block(s):	_	Stained		Ш	Ordering Physician Name NPI#
☐ Paraffin block(s): Stained Sta				attach	Ш	Medicare and other third party payors require services be medically necessary for
NOTE: Flow Cytometry and FISH (non-paraffin): Heparin preferred, EDTA acceptable Cytogenetics: Heparin only PCR (non-paraffin): EDTA preferred, Heparin acceptable				OTA acceptable		overage and generally do not cover routine screening tests.
	CR (non-paraffin): TINFORMATIO		EDTA preferred, Hepa	arin acceptable	4	BILLING INFO (Complete & accurate information must be provided, including billing instruction, or requesting entity will be billed)
PATIEN	TINFORMATIO	/IN				BILL: Insurance* Patient Requesting entityt
Name (La	ast, First, MI)				ш	ICD-10
DOB		□ Male □	Female SSN#			
	Accession #				П	If 3rd party billing is requested, a copy of face sheet and front/back of patients ins/Medicare card must be attached, or client will be billed. Direct-bill regulations prohibit PhenoPath from billing a 3rd party entity if requesting entity has been selected, ENTIRE billing demographics MUST be documented below f pre-authorization is required but is not obtained, PhenoPath will bill the requesting entity
					Ш	r pre-authorization is required but is not obtained, PhenoPath will bill the requesting entity Attn: Entity Name
					Ш	Department Address
i none_					Ш	City, State Zip
	npatient 🗖 🕻	Outnatient	t □ Non-Hosn	ital Patient		Person completing form
					Ш	Date Phone
						ne of the treating physician) NOT COMPLETED, report will NOT be faxed or mailed
	.,		<u> </u>			
	Address			Fa		ty Name: Phone Fax
	L HISTORY					
CLINICA	LIIIJIONI					SPECIAL INSTRUCTIONS
CLINICA	LIIISTORI					SPECIAL INSTRUCTIONS
CLINICA	LINSTORT					SPECIAL INSTRUCTIONS
CLINICA	E HISTORI					
CLINICA	ETHISTORY					MOLECULAR: Hematologic malignancies AML Panel*:
CLINICA	ETHISTORY					MOLECULAR: Hematologic malignancies □ AML Panel*: □ FLT3* □ NPM1* □ CEBPA* □ IDH1/IDH2* □ BCR-ABL1 major & minor □ BCR-ABL1 major (p210) only □ BCR-ABL1 minor (p190 only)
						MOLECULAR: Hematologic malignancies □ AML Panel*: □ FLT3* □ NPM1* □ CEBPA* □ IDH1/IDH2*
FLOW C	YTOMETRY (diag	jnosis un	der considerati			MOLECULAR: Hematologic malignancies AML Panel*: FLT3* NPM1* CEBPA* IDH1/IDH2* BCR-ABL1 major & minor BCR-ABL1 major (p210) only BCR-ABL1 minor (p190 only) JAK2 V617F JAK2 V617F (if negative, order JAK2 Exon 12-14*) (PV) JAK2 V617F (if negative, perform CALR, and if CALR is negative, order MPL*) (ET/PMF)
FLOW C	YTOMETRY (diag ometry analysis based shoproliferative disorde	ynosis un on clinical hi er 🔲	der considerati story and to rule out: Myeloid neoplasm			MOLECULAR: Hematologic malignancies AML Panel*: FLT3* NPM1* CEBPA* IDH1/IDH2* BCR-ABL1 major & minor BCR-ABL1 major (p210) only BCR-ABL1 minor (p190 only) JAK2 V617F JAK2 V617F (if negative, order JAK2 Exon 12-14*) (PV) JAK2 V617F (if negative, perform CALR, and if CALR is negative, order MPL*) (ET/PMF) JAK2 Exon 12-14*
FLOW C	YTOMETRY (diagonetry analysis based shoproliferative disordenative disor	Inosis un on clinical hi er	der considerati story and to rule out:			MOLECULAR: Hematologic malignancies AML Panel*: FLT3* NPM1* CEBPA* IDH1/IDH2* BCR-ABL1 major & minor BCR-ABL1 major (p210) only BCR-ABL1 minor (p190 only) JAK2 V617F JAK2 V617F (if negative, order JAK2 Exon 12-14*) (PV) JAK2 V617F (if negative, perform CALR, and if CALR is negative, order MPL*) (ET/PMF)
FLOW C Flow cyt Lymp Plasn PNH Perform	YTOMETRY (diagometry analysis basedohoproliferative disordona cell neoplasm (FLAER)	ynosis un on clinical hi er	der considerati story and to rule out: Myeloid neoplasm Acute leukemia Other low cytometry finding	on)	-	MOLECULAR: Hematologic malignancies AML Panel*: FLT3* NPM1* CEBPA* IDH1/IDH2* BCR-ABL1 major & minor BCR-ABL1 major (p210) only BCR-ABL1 minor (p190 only) JAK2 V617F JAK2 V617F (if negative, order JAK2 Exon 12-14*) (PV) JAK2 Exon 12-14* Calreticulin Exon 9 (CALR) MPL (W515)* MYD88 L265P
FLOW C Flow cyt Lymp Plasn PNH Perform Perform	YTOMETRY (diagometry analysis based shoproliferative disorder (FLAER) FISH studies if indicate	Inosis un on clinical hi er	der considerati story and to rule out: Myeloid neoplasm Acute leukemia Other if	on)	-	MOLECULAR: Hematologic malignancies AML Panel*:
FLOW C Flow cyt Lymp Plasn PNH Perform Studi	YTOMETRY (diagometry analysis based shoproliferative disorden a cell neoplasm (FLAER) FISH studies if indicate rm es to be determined by molecular studies if in	on clinical hier	der considerati story and to rule out: Myeloid neoplasm Acute leukemia Other low cytometry finding if pathologists d on flow cytometry i	on)	-	MOLECULAR: Hematologic malignancies AML Panel*: FLT3* NPM1* CEBPA* IDH1/IDH2* BCR-ABL1 major & minor BCR-ABL1 major (p210) only BCR-ABL1 minor (p190 only) JAK2 V617F JAK2 V617F (if negative, order JAK2 Exon 12-14*) (PV) JAK2 V617F (if negative, perform CALR, and if CALR is negative, order MPL*) (ET/PMF) JAK2 Exon 12-14* Calreticulin Exon 9 (CALR) MPL (W515)* MYD88 L265P MYD88 L265P (if negative, order CXCR4*)
FLOW C Flow cyt Lymp Plasn PNH Perform Studi Perford	YTOMETRY (diagometry analysis based shoproliferative disorden a cell neoplasm (FLAER) FISH studies if indicate rm es to be determined by molecular studies if in	Inosis un on clinical hi er ed based on f y PhenoPath dicated base	der considerati story and to rule out: Myeloid neoplasm Acute leukemia Other low cytometry finding if pathologists d on flow cytometry i	on)		MOLECULAR: Hematologic malignancies AML Panel*:
FLOW C Flow cyt Lymp Plasn PNH Perform Studi Perform Studi CYTOGE	YTOMETRY (diagometry analysis based shoproliferative disorden a cell neoplasm (FLAER) FISH studies if indicate rm es to be determined by molecular studies if in rm es to be determined by NETICS	Inosis un on clinical hi er ed based on f y PhenoPath dicated base	der considerati story and to rule out: Myeloid neoplasm Acute leukemia Other low cytometry finding if pathologists d on flow cytometry i	on)		MOLECULAR: Hematologic malignancies AML Panel*:
FLOW C Flow cyt Lymp Plasn PNH Perform Studi Perform Studi CYTOGE Chromos	YTOMETRY (diagometry analysis based shoproliferative disorden a cell neoplasm (FLAER) FISH studies if indicate rm es to be determined by molecular studies if in rm es to be determined by NETICS some analysis	Inosis un on clinical hi er ed based on f y PhenoPath dicated base	der considerati story and to rule out: Myeloid neoplasm Acute leukemia Other low cytometry finding if pathologists d on flow cytometry i	on)		MOLECULAR: Hematologic malignancies AML Panel*:
FLOW C Flow cyt Lymp Plasn PNH Perform Perform Studi CYTOGE Chromos	YTOMETRY (diagometry analysis based obhoproliferative disorden a cell neoplasm (FLAER) FISH studies if indicate rm es to be determined by molecular studies if in rm es to be determined by the studies if in studies in the studies in	on clinical hi er	der considerati story and to rule out: Myeloid neoplasm Acute leukemia Other low cytometry finding if pathologists d on flow cytometry fi if pathologists	on) gs indings		MOLECULAR: Hematologic malignancies AML Panel*:
FLOW C Flow cyt Lymp Plasn PNH Perform Studi Perform CYTOGE Chromos FISH PA	YTOMETRY (diagonetry analysis based shoproliferative disorden a cell neoplasm (FLAER) FISH studies if indicate remes to be determined by molecular studies if in remes to be determined by NETICS some analysis NELS Probes vary by vendo	on clinical hier	der considerati story and to rule out: Myeloid neoplasm Acute leukemia Other low cytometry finding if pathologists d on flow cytometry i jf pathologists	on) gs findings	-	MOLECULAR: Hematologic malignancies AML Panel*:
FLOW C Flow cyt Lymp Plasn PNH Perform Perform Studi CYTOGE Chromos	YTOMETRY (diagometry analysis based obhoproliferative disorden a cell neoplasm (FLAER) FISH studies if indicate rm es to be determined by molecular studies if in rm es to be determined by the studies if in studies in the studies in	on clinical hi er	der considerati story and to rule out: Myeloid neoplasm Acute leukemia Other low cytometry finding if pathologists d on flow cytometry finding if pathologists	on) gs findings t Services for details		MOLECULAR: Hematologic malignancies AML Panel*:
FLOW C Flow cyt Lymp Plasn PNH Perform Perfor Studi CYTOGE Chromos FISH PA ALL*:	YTOMETRY (diagonetry analysis based obhoproliferative disorden a cell neoplasm (FLAER) FISH studies if indicate rm es to be determined by molecular studies if in rm es to be determined by the studies if in studies if in rm to be determined by the studies if in studies if in rm to be determined by the studies if in studies if in rm to be determined by the studies in the studies i	on clinical hier	der considerati story and to rule out: Myeloid neoplasm Acute leukemia Other low cytometry finding if pathologists d on flow cytometry fi jf pathologists tact PhenoPath Clien nv16 Brk t(8;21) f	on) gs findings t Services for details		MOLECULAR: Hematologic malignancies AML Panel*:
FLOW C Flow cyt	YTOMETRY (diagonetry analysis based shoproliferative disorder a cell neoplasm (FLAER) FISH studies if indicate rm es to be determined by molecular studies if in rm es to be determined by NETICS some analysis NELS Probes vary by vendo t(15;17) PML/RARA MLL (11q23) Brk to t(15;17) PML/RARA	on clinical hier	der considerati story and to rule out: Myeloid neoplasm Acute leukemia Other low cytometry finding if pathologists d on flow cytometry fi jf pathologists tact PhenoPath Clien nv16 Brk t(8;21) f	on) gs findings t Services for details		MOLECULAR: Hematologic malignancies AML Panel*:
FLOW C Flow cyt Flow cyt Plasn Perform Studi Perform CYTOGE Chromos FISH PA ALL*: AML: CML:	YTOMETRY (diagometry analysis based shoproliferative disorden a cell neoplasm (FLAER) FISH studies if indicate from the color of the co	on clinical hier	der considerati story and to rule out: Myeloid neoplasm Acute leukemia Other low cytometry finding if pathologists d on flow cytometry fi jf pathologists tact PhenoPath Clien nv16 Brk t(8;21) f	on) gs findings t Services for details		MOLECULAR: Hematologic malignancies AML Panel*: FLT3* NPM1* CEBPA* IDH1/IDH2* BCR-ABL1 major & minor BCR-ABL1 major (p210) only BCR-ABL1 minor (p190 only) JAK2 V617F JAK2 V617F (if negative, order JAK2 Exon 12-14*) (PV) JAK2 V617F (if negative, perform CALR, and if CALR is negative, order MPL*) (ET/PMF) JAK2 Exon 12-14* Calreticulin Exon 9 (CALR) MPL (W515)* MYD88 L265P MYD88 L265P MYD88 L265P (if negative, order CXCR4*) BRAF V600 (for hairy cell leukemia) CLL/SLL Prognostic Panel*: GlyH mutation analysis (CLL)* NOTCH1* SF3B1* TP53* Gene Rearrangement Studies GlyH Gly-Kappa Gly-Kappa Gly-Kappa Gly-Kappa TCR-gamma TCR-beta TCR-gamma TCR-beta TCR-gamma & TCR-beta TCR-gamma (if negative, perform TCR-beta) CLL/SLL: Gly-Kappa Gl
FLOW C Flow cyt	YTOMETRY (diagonetry analysis based shoproliferative disorder a cell neoplasm (FLAER) FISH studies if indicate rm es to be determined by molecular studies if in rm es to be determined by NETICS some analysis NELS Probes vary by vendo t(15;17) PML/RARA MLL (11q23) Brk to t(15;17) PML/RARA	gnosis un on clinical hi er ded based on f y PhenoPath dicated base y PhenoPath or; please con description CBFB i 7/del 7q description RARA	der considerati story and to rule out: Myeloid neoplasm Acute leukemia Other low cytometry finding if pathologists d on flow cytometry i jf pathologists tact PhenoPath Clien nv16 Brk	on) gs findings t Services for details RUNX1/RUNX1T1 EGR1 (5q31/5p15.5)		MOLECULAR: Hematologic malignancies AML Panel*: FLT3* NPM1* CEBPA* IDH1/IDH2* BCR-ABL1 major & minor BCR-ABL1 major (p210) only BCR-ABL1 minor (p190 only) JAK2 V617F If negative, order JAK2 Exon 12-14* (PV) JAK2 V617F If negative, perform CALR, and if CALR is negative, order MPL*) (ET/PMF) JAK2 Exon 12-14* Calreticulin Exon 9 (CALR) MPL (W515)* MYD88 L265P MYD88 L265P MYD88 L265P MYD88 L265P IgH mutation analysis (CLL)* NOTCH1* SF3B1* TP53* Gene Rearrangement Studies IgH Ig-Kappa IgH & IgH Brk**
FLOW C Flow cyt I symp Plasn Plasn Perfor Studi Perform Perfo Studi CYTOGE Chromos FISH PA ALL*: AML: CML: MDS:	YTOMETRY (diagonetry analysis based oboproliferative disorder a cell neoplasm (FLAER) FISH studies if indicate results in the collection of the collection o	on clinical hier	der considerati story and to rule out: Myeloid neoplasm Acute leukemia Other low cytometry finding if pathologists d on flow cytometry fi jf pathologists tact PhenoPath Clien nv16 Brk t(8;21) fi cep8 (trisomy) Brk**	on) gs findings at Services for details RUNX1/RUNX1T1 BEGR1 (5q31/5p15.5)		MOLECULAR: Hematologic malignancies
FLOW C Flow cyt	YTOMETRY (diagometry analysis based shoproliferative disordina cell neoplasm (FLAER) FISH studies if indicate rim es to be determined by molecular studies if in rim es to be determined by NETICS some analysis NELS Probes vary by vendo 1 t(15;17) PML/RARA 1 t(15;17) PML/RARA 1 t(9;22) BCR/ABL** 1 EGR1 (5q31/5p15.5	gnosis un on clinical hi er ded based on f y PhenoPath dicated base y PhenoPath draw GBFB i 7/del 7q ** RARA	der considerati story and to rule out: Myeloid neoplasm Acute leukemia Other low cytometry finding if pathologists d on flow cytometry if pathologists tact PhenoPath Clien nv16 Brk	on) gs findings t Services for details RUNX1/RUNX1T1 EGR1 (5q31/5p15.5) CEP8 (trisomy) trisomy)		MOLECULAR: Hematologic malignancies AML Panel*: FLT3* NPM1* CEBPA* IDH1/IDH2* BCR-ABL1 major & minor BCR-ABL1 major (p210) only BCR-ABL1 minor (p190 only) JAK2 V617F AK2 V617F (if negative, order JAK2 Exon 12-14*) (PV) JAK2 V617F (if negative, perform CALR, and if CALR is negative, order MPL*) (ET/PMF) JAK2 Exon 12-14* Calreticulin Exon 9 (CALR) MPL (W515)* MYD88 L265P MYD88 L265P MYD88 L265P MYD88 L265P MYD88 L265P MYD88 L265P If negative, order CXCR4*) BRAF V600 (for hairy cell leukemia) CLL/SLL Prognostic Panel*: IgVH mutation analysis (CLL)* NOTCH1* SF3B1* TP53* Gene Rearrangement Studies IgH Ig-Kappa IgH (if negative, perform Ig-Kappa) TCR-gamma TCR-beta TCR-gamma & TCR-beta TCR-gamma (if negative, perform TCR-beta) CLL/SLL: 17p13.1_P53 11q22.3_ATM 13q14.3_D135319 13q34_LAMP CEP12 (trisomy) IGH Brk** t(11;14) CCND1/IGH** MALT1 Panel: MALT1 Brk** IGH Brk** BCL6 Brk** MALT1 Brk** IGH Brk** IGH Brk** BCL6 Brk** BCL6 Brk** If MALT1 Brk** IGH Brk** IGH Brk** BCL6 Brk** BCL6 Brk** If MYC +, run t(8;14) MYC/IGH Myeloma (algorithmic panel; CEPs may not be run): 17p13.1_P53 13q14.3_D135319 13q34_LAMP If 17p13.1_P53 14g1+1p21 14g1-1p21 14g1-1p21 14g1-1p2
FLOW C Flow cyt	YTOMETRY (diagometry analysis based shoproliferative disorden a cell neoplasm (FLAER) FISH studies if indicate rm es to be determined by molecular studies if in rm es to be determined by NETICS some analysis NELS Probes vary by vendo t(15;17) PML/RARA MLL (11q23) Brk t(15;17) PML/RARA t(19;22) BCR/ABL** □ t(9;22) BCR/ABL** □ EGR1 (5q31/5p15.5 □ 13q14.3_D13S319 □ CEP9 (hyperdiploid t tests listed in a panel metal)	on clinical hier	der considerati story and to rule out: Myeloid neoplasm Acute leukemia Other low cytometry finding if pathologists d on flow cytometry i if pathologists tact PhenoPath Clien nv16 Brk (8;21) F CEP8 (trisomy) Brk**	on) gs findings t Services for details RUNX1/RUNX1T1 EGR1 (5q31/5p15.5) CEP8 (trisomy) trisomy)	e-in	MOLECULAR: Hematologic malignancies

By submitting a specimen with this requisition form, you agree:

- 1) The information provided on this form and accompanying paperwork is complete and accurate.
- 2) If the information is not accurate, and PhenoPath cannot obtain reimbursement for services that have been requested and provided, Client agrees to accept financial responsibility.
- 3) If a service does not have an established Medicare allowable, PhenoPath will bill the Client.
- 4) If the test order is ambiguous, PhenoPath may contact client to determine intent. Testing may be delayed.
- 5) Requests for testing PhenoPath does NOT perform (for current test menu, consult PhenoPath's website www.phenopath.com or contact Client Services at 206.374.9000, or Toll-free at 888.92.PHENO (888.927.4366):
 - a) PhenoPath may forward specimens to an alternate facility for testing it does not perform, upon authorization by Client.
 - b) PhenoPath will manage return of applicable specimen to Client.
 - c) By signing the authorization form, Client agrees to pay for authorized services that are not paid for by a third party. PhenoPath can only bill for professional services provided by PhenoPath.

ICD-10 – All providers, laboratories, institutions, hospitals and other providers ordering laboratory testing to be performed by PhenoPath Laboratories must provide all clinically relevant ICD-10-CM diagnosis codes for all testing submitted.

Direct Bill Law – Washington is a "direct-bill" state for anatomic pathology services (http://apps.leg.wa.gov/rcw/default.aspx?cite=48.43.081, RCW 48.43.081). This means that PhenoPath can only send a bill to the entity that ordered the services (or to the patient or their insurance). We cannot bill a 3rd party.

MEDICARE COVERAGE DETERMINATIONS – PhenoPath is a Medicare participating provider, and is subject to the local coverage determinations (LCD) of the Medicare Administrative Contractor (MAC) for Jurisdiction F, Noridian Healthcare Solutions, Contractor No. 02402. Additional information can be obtained online at: https://www.noridianmedicare.com/partb/coverage/active.html.

PRE-AUTHORIZATION – If pre-authorization is required but is not obtained, and the insurance company denies payment due to lack of pre-authorization, the requesting entity will be billed.

MEDICARE MEDICAL NECESSITY REQUIREMENTS – When ordering laboratory tests that are billed to Medicare/Medicaid or other federally funded programs, the following requirements may apply:

- 1) Only tests that are medically necessary for the diagnosis or treatment of the patient should be ordered. Medicare does not pay for screening tests, except for certain specifically approved procedures, and may not pay for non-FDA-approved tests or tests considered experimental.
- 2) If there is reason to believe that Medicare will not pay for a test, the patient should be informed, and asked to sign an Advance Beneficiary Notice (ABN) to indicate whether he/she accepts responsibility for the cost of the test if Medicare denies payment.
- 3) The ordering physician must provide all clinically relevant ICD-10 diagnosis codes, not a narrative description, in order to support the medical necessity of each test ordered. Providing ICD-10 codes on the Requisition will avoid unnecessary phone calls to physician and client offices as well as delays in service to patients to obtain medical necessity documentation. PhenoPath may contact Client to obtain diagnosis information for reasons including, but not limited to the following:
 - A diagnosis code is not provided.
 - The provided diagnosis appears inconsistent with the patient's demographic, the patient's medical condition, or the testing services being ordered.
 - The provided diagnosis does not meet the coverage criteria as supporting medical necessity for testing services covered by a Medicare LCD.
- 4) Organ- or disease-oriented panels should be billed to Medicare only when every component of the panel is medically necessary. The OIG takes the position that a physician who orders medically unnecessary tests for which Medicare reimbursement is claimed may be subject to civil penalties. PhenoPath- and client-customized panels should be billed to Medicare only when every component of the customized panel is medically necessary. PhenoPath offers groups of tests based on accepted clinical practice.

Advanced Beneficiary Notice ("ABN") – An ABN, Form CMS-R-131, is a standardized notice you must issue to a Medicare beneficiary before providing certain Medicare Part B (outpatient) or Part A (limited to hospice, home health agencies [HHAs], and Religious Nonmedical Healthcare Institutions only) items or services. You must issue the ABN when:

- You believe Medicare may not pay for an item or service;
- Medicare usually covers the item or service; and
- Medicare may not consider the item or service medically reasonable and necessary for this patient in this particular instance. You should only provide ABNs to beneficiaries enrolled in original (fee-for-service) Medicare. ABNs allow beneficiaries to make informed decisions about whether to get services and accept financial responsibility for those services if Medicare does not pay. The ABN serves as proof the beneficiary knew prior to getting the service that Medicare might not pay. If you do not issue a valid ABN to the beneficiary when Medicare requires it, you cannot bill the beneficiary for the service, and you may be financially liable if Medicare doesn't pay. You may also use the ABN as an optional (voluntary) notice to alert beneficiaries of their financial liability prior to providing care that Medicare never covers. ABN issuance is not required to bill a beneficiary for an item or service that is not a Medicare benefit and never covered.
- If you order a test that does not meet Medicare's medical necessity guidelines, it is important that you complete an ABN and have it signed by the patient at the time of service. This will allow you and PhenoPath to bill the patient for the services provided if Medicare does not reimburse us for the test(s) and if the patient has accepted the financial responsibility. Medicare defines medical necessity as services that are: reasonable and necessary, for the diagnosis or treatment of an illness or injury or to improve the functioning of a malformed body member, and not excluded under another provision of the Medicare Program. All services reported to the Medicare Program by health care professionals must demonstrate medical necessity through the use of International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM) diagnostic coding carried to the highest level of specificity for the date of service.
- If the testing does not meet Medicare medical necessity guidelines, the patient does not sign an ABN, and Medicare fails to reimburse for the test(s) ordered, PhenoPath will bill the referring lab/physician for the services provided.

PhenoPath's billing practices have been developed to ensure compliance with federally mandated rules. Direct questions about invoices to our Medical Billing department at 1-866-927-4366 or 206-374-1480. Fax inquiries to 206-774-3412. The department is generally staffed Monday to Friday from 6 am to 4:30 pm Pacific time.

Physician Clinical Consultant: PhenoPath's pathologists are available to discuss appropriate testing and test ordering with ordering physicians.

